Form 4 for LUCD Lucid Diagnostics Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-20 · accession 0001094891-26-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | 2026-02-20 | LUCD | Aklog Lishan | CEO, Dir | A - Grant | $0.00 | +2.17M | 3.64M | +148% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-20 | A | A | 2,170,000 | $0.00 | 3,636,627 | D | — | — | (F1) Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |